Business
Guardant Health Introduces GuardantINFINITY™ Smart Liquid Biopsy for Research Use to Help Bring New Cancer Therapies to Patients Sooner
Next-generation assay combines 800+-gene panel with exome-wide methylation detection to provide novel genomic and epigenomic insights into tumor, tumor
About this update from Guardant Health, Inc.
[{"type":"text","content":"\n\nNext-generation assay combines 800+-gene panel with exome-wide methylation detection to provide novel genomic and epigenomic insights into tumor, tumor microenvironment and patient immune responses from a simple blood draw\n\n\nResearchers can access additional modular content to gain insight into and direct patient selection for IO, HRD and other targeted therapies with no need for additional sample collection\n\n\n PALO ALTO, Calif.--(BUSINESS WIRE)--\nGuardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today the introduction of GuardantINFINITY™, a next-generation liquid biopsy that provides new, multi-dimensional insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development.\n\nThe new GuardantINFINITY assay provides a more comprehensive molecular profile of tumors than earlier assays, giving researchers access to novel genomic and epigenomic insights to provide a simultaneously deeper and more complete understanding of a tumor’s biology, its system-wide interactions and the associated immune response in a range of applications—from therapy selection to molecular response and longitudinal monitoring. The assay’s extensive methylome panel helps identify the unique, exome-wide methylation pattern that each tumor delivers, providing an important new dimension of research insights that has been largely unexplored in clinical development to date.\n\n“Realizing the promise of precision medicine demands a comprehensive, multi-dimensional understanding of the tumor, the tumor microenvironment and the patient’s immune response,” said Helmy Eltoukhy, Guardant Health co-CEO. “GuardantINFINITY, the first product from our new smart liquid biopsy platform, represents a quantum leap forward in the capabilities of liquid biopsies to provide those insights. Drawing on 10 years of research and experience from hundreds of thousands of liquid biopsies, this new assay allows researchers to gain unprecedented insight into a tumor’s molecular underpinnings and its systemic complex interactions to help them accelerate the development of much-needed cancer therapies.”\n\nThe new platform will enable countless new liquid biopsy applications over time, from deep interrogation of the tumor microenvironment to diverse immuno-oncology applications, muc...